Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice

被引：6
|
作者：
Froberg, Gabrielle [1 ,2 ]
Jansson, Lena [1 ]
Bruchfeld, Judith [1 ,2 ]
机构：
[1] Karolinska Univ Hosp, Dept Infect Dis, B2 00, S-17176 Stockholm, Sweden
[2] Karolinska Inst, Div Infect Dis, Dept Med Solna, Stockholm, Sweden
来源：
EUROPEAN RESPIRATORY JOURNAL | 2019年 / 53卷 / 02期
关键词：
INFECTION; RIFAPENTINE;
D O I：
10.1183/13993003.01128-2018
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection
    Pease, Christopher
    Hutton, Brian
    Yazdi, Fatemeh
    Wolfe, Dianna
    Hamel, Candyce
    Barbeau, Pauline
    Skidmore, Becky
    Alvarez, Gonzalo G.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 (06) : 557 - 566
  • [32] Compliance with Isoniazid treatment of latent tuberculosis infection
    Eidlitz-Markus, T
    Zeharia, A
    Baum, G
    Mimouni, M
    Amir, J
    PEDIATRIC RESEARCH, 2003, 53 (04) : 326A - 326A
  • [33] Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine
    Adelaide H. McClintock
    McKenna Eastment
    Christy M. McKinney
    Caroline L. Pitney
    Masahiro Narita
    David R. Park
    Shireesha Dhanireddy
    Alexandra Molnar
    BMC Infectious Diseases, 17
  • [34] Treatment for Preventing Tuberculosis in Children and Adolescents A Randomized Clinical Trial of a 3-Month, 12-Dose Regimen of a Combination of Rifapentine and Isoniazid
    Villarino, M. Elsa
    Scott, Nigel A.
    Weis, Stephen E.
    Weiner, Marc
    Conde, Marcus B.
    Jones, Brenda
    Nachman, Sharon
    Oliveira, Ricardo
    Moro, Ruth N.
    Shang, Nong
    Goldberg, Stefan V.
    Sterling, Timothy R.
    JAMA PEDIATRICS, 2015, 169 (03) : 247 - 255
  • [35] Iadhere Study: Cost-Effectiveness Of Self-Administered Isoniazid/rifapentine For Treatment Of Latent Tuberculosis Infection In The United States
    Holland, D. P.
    Sheehan, D.
    Wright, A.
    Scott, N. A.
    Belknap, R. W.
    Borisov, A. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [36] Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study
    Sterling, Timothy R.
    Moro, Ruth N.
    Borisov, Andrey S.
    Phillips, Elizabeth
    Shepherd, Gillian
    Adkinson, Newton Franklin
    Weis, Stephen
    Ho, Christine
    Villarino, Margarita Elsa
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (04) : 527 - 535
  • [37] Drug–Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection
    Catia Marzolini
    Sara Gibbons
    Joep J. van Oosterhout
    Saye Khoo
    Clinical Pharmacokinetics, 2022, 61 : 339 - 346
  • [38] RELATIVE EFFICACY OF ISONIAZID THERAPY FOR 12 WEEKS, 24 WEEKS, OR 52 WEEKS IN PREVENTING TUBERCULOSIS
    THOMPSON, NJ
    SNIDER, DE
    FARER, LS
    CHEST, 1979, 76 (03) : 368 - 368
  • [39] Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events
    Lin, Shang-Yi
    Chiu, Yi-Wen
    Lu, Po-Liang
    Hwang, Shang-Jyh
    Chen, Tun-Chieh
    Hsieh, Min-Han
    Chen, Yen-Hsu
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2019, 52 (01) : 158 - 162
  • [40] Antepartum or postpartum isoniazid treatment of latent tuberculosis infection
    Boggess, KA
    Myers, ER
    Hamilton, CD
    OBSTETRICS AND GYNECOLOGY, 2000, 96 (05): : 757 - 762
12345